Telephone
61.2.9870.7580
Address
7 Eliza Street Newtown, New South Wales (NSW) 2042
Description
Genetic Signatures Ltd. is a molecular diagnostics company, which focuses on the development of real-time PCR based products for the routine detection of infectious diseases. Its molecular diagnostics, 3Base, provides high-volume hospital and pathology laboratories with the ability to screen wide array of infectious pathogens. The firm also designs and manufactures suite of real-time polymerase chain reaction based products for the routine detection of infectious diseases under the EasyScreen brand. The company was founded by Robert J. Birrell, Christopher M. Abbott, and Geoffrey Grigg on February 15, 2001 and is headquartered in Newtown, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.44 - 1.0
Trade Value (12mth)
AU$14,067.00
1 week
4.04%
1 month
3%
YTD
-42.78%
1 year
-43.09%
All time high
2.94
EPS 3 yr Growth
497.600%
EBITDA Margin
-102.50%
Operating Cashflow
-$12m
Free Cash Flow Return
-25.50%
ROIC
-28.80%
Interest Coverage
-17,365.00
Quick Ratio
4.50
Shares on Issue (Fully Dilluted)
143m
HALO Sector
Industrials
Next Company Report Date
28-Aug-24
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.10
Date | Announcements |
---|---|
31 October 22 |
Change of Registry Address
×
Change of Registry Address |
31 July 23 |
Quarterly update and Appendix 4C
×
Quarterly update and Appendix 4C |
31 August 23 |
Appendix 4E and Annual Report
×
Appendix 4E and Annual Report |
31 August 23 |
Appendix 4G and Corporate Governance Statement
×
Appendix 4G and Corporate Governance Statement |
31 August 22 |
Full Year Statutory Accounts
×
Full Year Statutory Accounts |
30 September 22 |
Annual Report to shareholders
×
Annual Report to shareholders |
30 September 22 |
Appendix 4G and Corporate Governance Statement
×
Appendix 4G and Corporate Governance Statement |
30 October 23 |
Quarterly update and Appendix 4C
×
Quarterly update and Appendix 4C |
30 March 22 |
Public Health Wales Awards Enteric Testing Contract to GSS
×
Public Health Wales Awards Enteric Testing Contract to GSS |
30 January 23 |
Quarterly update and Appendix 4C
×
Quarterly update and Appendix 4C |
29 September 22 |
3base Kit for Antimicrobial Resistance Shows High Detection
×
3base Kit for Antimicrobial Resistance Shows High Detection |
29 October 18 |
2018 Annual Report to Shareholders
×
2018 Annual Report to Shareholders |
29 October 18 |
Notice of Annual General Meeting/Proxy Form
×
Notice of Annual General Meeting/Proxy Form |
29 November 23 |
2023 AGM Chairman's Address and CEO Presentation
×
2023 AGM Chairman's Address and CEO Presentation |
29 November 23 |
AGM Results of Meeting
×
AGM Results of Meeting |
29 November 18 |
Withdrawal of resolution 4 from 2018 Annual General Meeting
×
Withdrawal of resolution 4 from 2018 Annual General Meeting |
29 November 18 |
Results of Annual General Meeting
×
Results of Annual General Meeting |
29 November 16 |
2016 AGM MD and CEO Presentation
×
2016 AGM MD and CEO Presentation |
29 May 20 |
Investor Presentation
×
Investor Presentation |
28 September 15 |
Date of Annual General Meeting
×
Date of Annual General Meeting |
28 October 19 |
Investor presentation - capital raise
×
Investor presentation - capital raise |
28 October 16 |
Notice of Annual General Meeting/Proxy Form
×
Notice of Annual General Meeting/Proxy Form |
28 October 16 |
Annual Report to shareholders
×
Annual Report to shareholders |
28 November 17 |
2017 AGM Presentation
×
2017 AGM Presentation |
28 July 20 |
Investor presentation
×
Investor presentation |
28 January 22 |
Investor presentation
×
Investor presentation |
28 August 20 |
Investor presentation
×
Investor presentation |
28 August 20 |
CEO presenting at ShareCafe webinar
×
CEO presenting at ShareCafe webinar |
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.